BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31351052)

  • 1. The strigolactone analog GR-24 inhibits angiogenesis in vivo and in vitro by a mechanism involving cytoskeletal reorganization and VEGFR2 signalling.
    Carrillo P; Martínez-Poveda B; Medina MÁ; Quesada AR
    Biochem Pharmacol; 2019 Oct; 168():366-383. PubMed ID: 31351052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
    Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
    Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.
    Chuang IC; Yang CM; Song TY; Yang NC; Hu ML
    Life Sci; 2015 Oct; 139():52-61. PubMed ID: 26285173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
    Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
    Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells.
    Lin C; Wu M; Dong J
    PLoS One; 2012; 7(2):e31708. PubMed ID: 22348123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
    Yu Y; Cai W; Pei CG; Shao Y
    Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells.
    Wang S; Cai R; Ma J; Liu T; Ke X; Lu H; Fu J
    Phytomedicine; 2015 Oct; 22(11):1017-26. PubMed ID: 26407944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
    Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells.
    Xing Y; Tu J; Zheng L; Guo L; Xi T
    Oncol Rep; 2015 Jan; 33(1):163-70. PubMed ID: 25376085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
    Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
    Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.